Cargando…
37. IN VIVO FUNCTIONAL GENOMIC SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS
Brain metastasis, the most common tumour of the central nervous system, occurs in 20–36% of primary cancers. In particular, 40% of patients with non-small cell lung cancer (NSCLC) develop brain metastases, with a dismal survival of approximately 4–11 weeks without treatment, and 16 months with treat...
Autores principales: | Aghaei, Nikoo, Lam, Fred, Venugopal, Chitra, Singh, Sheila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401360/ http://dx.doi.org/10.1093/noajnl/vdaa073.025 |
Ejemplares similares
-
NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis
por: Aghaei, Nikoo, et al.
Publicado: (2021) -
BSCI-18. Identifying novel drivers of lung-to-brain metastasis through in vivo functional genomics
por: Aghaei, Nikoo, et al.
Publicado: (2021) -
39. CHARACTERIZING NOVEL INHIBITORS OF BRAIN METASTASIS-INITIATING CELLS
por: Kieliszek, Agata, et al.
Publicado: (2020) -
47. UNCOVERING A NOVEL ROLE FOR HLA-G IN BRAIN METASTASES
por: Bassey-Archibong, Blessing, et al.
Publicado: (2020) -
BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis
por: Kieliszek, Agata, et al.
Publicado: (2021)